Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1976 Jun;3(3):439-43.
doi: 10.1111/j.1365-2125.1976.tb00619.x.

A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects

Clinical Trial

A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects

M J West et al. Br J Clin Pharmacol. 1976 Jun.

Abstract

1 Plasma concentrations of oxprenolol have been compared in six healthy volunteers after 80 and 160 mg doses of a new slow release (SR) oxprenolol preparation, after an 80 ng dose of conventional oxprenolol (CO), and after the second of two 80 mg doses of conventional oxprenolol given 12 h apart. Basal pulse rates and blood pressures, and pulse rates before and after a standard exercise test have been compared after the four active treatments and after a placebo. 2 Peak plasma concentrations of oxprenolol attained after 160 mg of the slow release preparation were similar to the peak concentrations after the single 80 mg dose of conventional oxprenolol. Higher concentrations, however, persisted for much longer after the slow release preparations than after the conventional preparations. 3 Neither oxprenolol formulation had any effect on resting pulse rate or blood pressure in normotensive volunteers. 4 Comparison with placebo showed that the single dose of the conventional oxprenolol produced a significant reduction in exercise induced tachycardia for 8 h whereas the high dose of the slow release preparation produced a similar reduction which lasted for at least 14 hours.

PubMed Disclaimer

Comment in

  • Bioavailability of beta-adrenoceptor blocking drugs.
    Johnsson G, Regardh CG. Johnsson G, et al. Br J Clin Pharmacol. 1976 Dec;3(6):1064-5; author reply 1066. doi: 10.1111/j.1365-2125.1976.tb00361.x. Br J Clin Pharmacol. 1976. PMID: 22216533 Free PMC article. No abstract available.

References

    1. J Pharm Pharmacol. 1973 Mar;25(3):256-7 - PubMed
    1. Eur J Clin Pharmacol. 1975;8(1):3-9 - PubMed
    1. Acta Pharmacol Toxicol (Copenh). 1975;36(Suppl 5):31-44 - PubMed
    1. Br Med J. 1973 Nov 3;4(5887):257-9 - PubMed
    1. J Pharmacokinet Biopharm. 1974 Aug;2(4):347-64 - PubMed